Dix-Peek, Thérèse http://orcid.org/0000-0002-7593-0857
Phakathi, Boitumelo P.
van den Berg, Eunice J.
Dickens, Caroline
Augustine, Tanya N.
Cubasch, Herbert
Neugut, Alfred I.
Jacobson, Judith S.
Joffe, Maureen
Ruff, Paul
Duarte, Raquel A. B. http://orcid.org/0000-0003-2750-2062
Funding for this research was provided by:
Division of Cancer Epidemiology and Genetics, National Cancer Institute (01-CA192627, 01-CA192627, 01-CA192627, 01-CA192627, P30-CA136696, P30-CA136696, P30-CA136696, P30-CA136696)
South African Medical Research Council (Common Epithelial Cancer Research Center)
South African National Research Foundation
University of the Witwatersrand
Article History
Received: 21 September 2022
Accepted: 3 February 2023
First Online: 3 March 2023
Declarations
:
: Dr. Neugut has consulted for Otsuka Pharmaceuticals, GlaxoSmithKline, United Biosource Corp., Eisai, Hospira, and Value Analytics. He is a member of the Medical Advisory Board of EHE Intl. He receives research funding from Otsuka Pharmaceuticals. Dr. Ruff has received Research Funding from MSD (Inst), Janssen Oncology (Inst), Roche (Inst), AstraZeneca (Inst), Novartis (Inst), Pfizer (Inst) and travel, accommodations expenses from Merck Serono, MSD Oncology, Pfizer, Dr Reddy’s Laboratories, AstraZeneca, Roche. No other conflicts of interest were reported.
: All participants consented to take part in the SABCHO study, and use of FFPE samples used in this study and the study was approved by the Human Research Ethics Committee (Medical) at the University of the Witwatersrand, # 161116. The study was performed in accordance with the declaration of Helsinki.
: All patients gave informed consent for the publication of the results and clinical information. Patient information was deidentified before analysis.